Abstract: Compounds selected from the group consisting of formulae III, IV, VI and VIII wherein R is H is NH2, or a pharmacologically acceptable salt thereof, are suitable for use in methods for treating non-insulin-dependent diabetes mellitus (NIDDM) or obesity in a patient susceptible to or experiencing NIDDM or obesity by the systemic administration of such a compound in an amount effective to treat the NIDDM or obesity.

Abstract: The present invention provides for the treatment of non-insulin dependent diabetes mellitus or obesity comprising the systemic administration of a compound having the formula or a pharmacologically acceptable salt thereof, wherein each R is H or NH2, and with the proviso that at least one R group must be NH2.

Abstract: The present invention provides novel compounds of the formulae (I): AG--(CH.sub.2).sub.n --CO.sub.2 R.sup.1 and (II) or pharmacologically acceptable salts thereof, wherein AG is: a) N-aminoguanidine, b) N,N'-diaminoguanidine, or c) N,N',N"-triaminoguanidine; and n, R.sup.1 and R.sup.2 have the meanings given in the description as well as a new use for the compounds of formula (III) wherein R.sup.3 has the meanings given in the description for the treatment of non-insulin dependent diabetes mellitus (NIDDM).

Abstract: The present invention provides novel compounds of the formula I and II for the treatment of non-insulin dependent diabetes mellitius (NIDDM) and a new use of known compounds for this purpose.

Abstract: The present invention provides novel compounds of the formulae I-VIII for the treatment of non-insulin dependent diabetes mellitus (NIDDM) and a new use of known compounds IX to X for this purpose.

Abstract: The present invention provides some novel 4-hydroxycoumarin-3-carboxamide derivatives and the use of a broad class of 4-hydroxycoumarin-3-carboxamide derivatives for the treatment of a patient suffering from or susceptible to diabetes mellitus.

Abstract: Pyrazoloazepino-substituted oximes, having the formula ##STR1## wherein R is ##STR2## where R.sup.5 is --(CH.sub.2).sub.c -- and c is 3-6 are disclosed. These compounds are useful for the treatment of atherosclerosis and hypercholesterolemia.

Abstract: Imidazopyridino- and pyrazolopyridino- substituted oximes are disclosed having the formulas ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and a are as described in the claims. for the treatment of atherosclerosis and hypercholesterolemia.

Abstract: Pyrrolidinopyrazole-substituted oximes having the formula ##STR1## are disclosed wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and a are as described in the claims for the treatment of atherosclerosis and hypercholesterolemia.

Abstract: New pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of formula (I), ##STR1## where R.sub.1, R.sub.2, R.sub.3, R.sub.4 and m are as defined in the specification, e.g., 4-(benzoylmethyl)-6-cyclohexyl-6,7-dihydro-2-phenyl-4H-pyrazolo[1,5-a]pyrr olo[3,4-d]pyrimidine-5,8-dione, have been found to be potentially useful to treat warm-blooded animal patients suffering from the symptoms of atherosclerosis and cholesterol buildup to relieve the same and for favorably altering the high density lipoprotein (HDL) to low density lipoprotein (LDL) ratio in blood samples of such patients.